孙永汇，研究员，博士生导师。2012年获得山东大学药学专业学士学位，2018年获得清华大学生物学专业博士学位。从事新型临床难成药/耐药靶点降解剂（PROTACs）开发及分子胶新技术研究。获得国家自然科学基金青年科学基金项目、北京市科技新星计划项目、清华大学“水木学者”计划资助。
     院校引进人才，2022年加入院校，曾在哈佛大学医学院、清华大学药学院开展研究工作，从事新型耐药蛋白降解机制探索和新型PROTAC/分子胶双机制蛋白降解剂研究。

长期从事新型靶向严重疾病相关蛋白降解PROTAC及分子胶新技术研究。开发了靶向临床耐药突变型BTKC481S蛋白降解剂，克服了临床一线药物ibrutinib的耐药性和毒副作用；设计并获得了靶向MELK蛋白降解剂及新型PROTAC/分子胶双机制降解剂；开发了可见光控分子胶降解剂，显著提高了癌症治疗效率并降低了传统治疗方案的毒性。主持2项国家级和省部级科研项目，在Cell Research、Leukemia、Chemical Science等杂志发表论文20余篇。主编英文PROTAC专著1部。授权抗肿瘤PROTAC专利2项。

1. Wei Yan#, Naizhen Zhang#, Xiao Liu#, Qiyu He, Xucheng Lv, Jianghui Sun, Lili Zhuang, Yuexin Zou, Yajie Zhang, Yuhang Liang, Yanjie Wang, Siyuan Li, and Yonghui Sun*. Development of visible-light photocaged molecular glues (vc-MGs) for B-cell malignancies therapy with improved safety and pharmacokinetic profiles in vivo. Chinese Chemical Letters. In Press. (2025. IF=8.9)

2. Yonghui Sun*, Xiao Liu, Qiyu He, Naizhen Zhang, Wei Yan, Xucheng Lv, and Yanjie Wang. Discovery of first-in-class PROTACs targeting maternal embryonic leucine zipper kinase (MELK) for the treatment of Burkitt lymphoma. RSC Medicinal Chemistry. 15 (7):2351. (2024. IF=4.1)

3. Yonghui Sun*#, Qiyu He#, Xucheng Lv, Naizhen Zhang, Wei Yan, Jianghui Sun, and Lili Zhuang. Switchable Site-Selective Benzanilide C(sp²)-H Bromination via Promoter Regulation. Molecules. 29 (12):2861. (2024. IF=4.2)

4. Yonghui Sun, Zimo Yang, Zhimin Zhang, Zhen Li, Liubin Guo, Hao Pan, Xin Luo, Dongzhou Liu, and Yu Rao* Design, synthesis, and evaluation of BTK-targeting PROTACs with optimized bioavailability in vitro and in vivo. RSC Medicinal Chemistry. 14 (8):1562. (2023. IF=4.1)

5. Yonghui Sun#, Xin Luo#, Zimo Yang, Wenxing Lv, Lixia Chen, Hua Li*, and Yu Rao*. Developing potent BTK^C481S PROTACs for ibrutinib-resistant malignant lymphoma. Chinese Chemical Letters. 34 (6):107924. (2022. IF=9.1)

6. Zimo Yang#, Yonghui Sun#, Zhihao Ni, Celi Yang, Yan Tong, Yujie Liu, Haitao Li, and Yu Rao*. Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently. Cell Research. 31(12):1315-1318. (2021. IF=25.617)

7. Yonghui Sun, Yu Rao*. Protein Degradation with New Chemical Modalities: Successful Strategies in Drug Discovery and Chemical Biology (Chapter 8). Drug Discovery, Royal Society of Chemistry ISBN: 978-1-78801-686-5. (2020)

8. Yonghui Sun#, Ning Ding#, Yuqin Song#, Zimo Yang, Wanli Liu*, Jun Zhu*, and Yu Rao*. Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas. Leukemia 33(8):2105-2110. (2019. IF=8.665)

9. Yonghui Sun#, Xingwang Zhao#, Ning Ding#, Hongying Gao#, Yue Wu, Yiqing Yang, Meng Zhao, Jinseok Hwang, Yuqin Song, Wanli Liu*, and Yu Rao*. PROTAC-induced BTK degradation as a novel therapy for mutated BTK^C481S induced ibrutinib-resistant B-cell malignancies. Cell Research 28(7):779-781. (2018. IF=17.848, C100)

10. Yonghui Sun#, Tianyu Sun#, Yundong Wu, Xinhao Zhang*, and Yu Rao*. A diversity-oriented synthesis of bioactive benzanilides via a regioselective C(sp²)-H hydroxylation strategy. Chemical Science 7(3):2229-2238. (2016. IF=8.668)